<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649922</url>
  </required_header>
  <id_info>
    <org_study_id>M03-600</org_study_id>
    <nct_id>NCT00649922</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immunogeneicity of the Influenza virus and standard 23-valent pneumococcal
      virus in subject with RA receiving adalimumab or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood samples for Influenza A &amp; B antibody Assay</measure>
    <time_frame>Baseline (Day 1), Day 36 or premature discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Samples for Pneumococcal Antibody Assay</measure>
    <time_frame>Baseline (Day 1), Day 36 or premature discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessments</measure>
    <time_frame>Screening, Week 15, Day 36, Month 3 and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals signs</measure>
    <time_frame>Screening - Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Screening - Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Double Blind</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29</description>
    <arm_group_label>Double Blind</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 injections Day 1, 1 injection Days 15 and 29</description>
    <arm_group_label>Double Blind</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg adalimumab every other week</description>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Females at least 20 years of age.

          -  Females post-menopausal for at least 1 year, surgically sterile, or practicing
             acceptable methods of birth control.

          -  Females have a negative pregnancy test at screening.

          -  Diagnosis of RA and met ACR criteria.

          -  Must discontinue any TNF at least 2 months prior to baseline.

          -  In condition of general good health.

        Exclusion Criteria:

          -  History of significant sensitivity to any drug; clinically significant drug or alcohol
             abuse within the past year; active infection with Listeria or TB; lymphoma or
             leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the
             exception of successfully treated non-metastatic basal cell or squamous cell carcinoma
             of skin or localized carcinoma in situ of the cervix.

          -  History of current acute inflammatory joint disease.

          -  Use of TAMIFLU or Symmetrel within 3 months of study drug administration.

          -  Recent (3 month) history of influenza or pneumococcal bacterial infection.

          -  Known positive human immunodeficiency virus (HIV) status.

          -  Positive hepatitis B or hepatitis C virus.

          -  Positive PPD &gt;5 mm.

          -  Chest x-ray with calcified granulomas and/or pleural scarring or significant
             abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lawrence McNamee, Sr. Clinical Research Manager</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Vaccines with adalimumab dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

